Trade

Pfizer share price

Moderate risk
  • 22%Low risk
  • 22%Moderate risk
  • 22%Balanced risk
  • 22%High risk
  • 22%Extreme risk
  • 4,585.75(-2.29%)
    February 6, 2026 15:24:01 PM IST
    • NSE
    • BSE
  • Vol : 10.03 K (NSE + BSE)
    Last 20 day avg : 11.87 K

Pfizer is trading -2.29% lower at Rs 4,585.75 as compared to its last closing price. Pfizer has been trading in the price range of 4,710.85 & 4,580.75. Pfizer has given -5.82% in this year & 2.93% in the last 5 days. Pfizer has TTM P/E ratio 27.45 as compared to the sector P/E of 23.40.There are 3 analysts who have initiated coverage on Pfizer. There are 2 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 189.02 Crores in its last quarter.Listed peers of Pfizer include Aurobindo Pharma (0.67%), Unichem Laboratories (-8.15%), Themis Medicare (0.24%).The Mutual Fund holding in Pfizer was at 11.71% in 31 Dec 2025. The MF holding has decreased from the last quarter. The FII holding in Pfizer was at 2.71% in 31 Dec 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Feb 08, 2026, 05:45 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.62
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.03
    In line with industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.75
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    5.10
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    25.60
    Lower than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    3.28
    Indicates overvaluation
Price range
Day Range
Lowest
4,580.75
Highest
4,710.85
52 week range
Lowest
3,659.74
Highest
5,878.55
Pfizer Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Aurobindo Pharma
Bullish
1,190.400.6769,109.4020.152.150.335.52
Unichem Laboratories
Bearish
395.00-8.152,827.3823.181.29-3.51
Themis Medicare
Moderately Bearish
84.220.24774.0131.812.350.494.62
Neuland Laboratories
Bearish
13,036.15-1.2416,834.4092.9612.690.087.17
Jagsonpal Pharmaceuticals
Bearish
168.50-1.521,121.5433.885.541.253.18
Mutual Fund Ownership
View all
Quant ESG Equity Fund Regular Growth
4/5
  • Amount Invested (Cr.) 24.99
  • % of AUM 8.36
Quant Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 27.08
  • % of AUM 6.49
DSP Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 112.63
  • % of AUM 3.80
SBI Innovative Opportunities Fund Regular Growth
NA
  • Amount Invested (Cr.) 227.07
  • % of AUM 3.08
Aditya Birla Sun Life MNC Fund Growth
NA
  • Amount Invested (Cr.) 95.17
  • % of AUM 2.59
Pfizer Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-02-09Quarterly Results
2025-11-12Quarterly Results
2025-08-13Quarterly Results
2025-05-19Audited Results & Special Dividend
2025-01-31Quarterly Results
About the company Pfizer
  • IndustryMajor Drugs
  • ISININE182A01018
  • BSE Code500680
  • NSE CodePFIZER
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
  • Management Info
  • Amit AgarwalChief Financial Officer, Executive Director - Finance
  • Meenakshi NevatiaManaging Director, Executive Director
  • Sharad GoswamiSenior Director - Policy and Public Affairs
  • Pankaj GuptaSenior Director - Medical Affairs
  • Manish PaliwalSenior Director - Regulatory Affairs
  • Anil PattanshettySenior Director - Business Operations
  • Pazhania RenganExecutive Director - Plant Operations
  • Saral GuptaDirector - Commercial Channel and Market Access
  • Prashant MahalingamCategory Lead - Internal Medicine
  • Aditi MehtaCategory Lead - Vaccines
Pfizer Share Price FAQs

Pfizer is trading at 4585.75 as on Fri Feb 06 2026 09:54:01. This is -2.29% lower as compared to its previous closing price of 4693.45.

The market capitalization of Pfizer is 20890.86 Cr as on Fri Feb 06 2026 09:54:01.

The average broker rating on Pfizer is Strong Buy. The breakup of analyst rating is given below -

  • 2 analysts have given a strong buy rating
  • 0.00 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Pfizer is 5878.55 whereas the 52 wk low is 3659.74

Pfizer can be analyzed on the following key metrics -

  • TTM P/E: 27.45
  • Sector P/E: 23.40
  • Dividend Yield: 0.75%
  • D/E ratio: 0.02

Pfizer reported a net profit of 767.60 Cr in 2025.

The Mutual Fund Shareholding was 11.71% at the end of 31 Dec 2025.